Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loxo Oncology Inc.

www.loxooncology.com

Latest From Loxo Oncology Inc.

US FDA's Top Tips For Tumor Agnostic Drug Development

'Although sponsors have conventionally focused on the development of a drug, the strategy of pursuing site-agnostic indications must focus on both drug and biomarker development,' FDA's Richard Pazdur and colleagues write in the New England Journal of Medicine.

Clinical Trials Research & Development

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Reimbursement Advisory Committees

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.

Pricing Strategies Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Loxo Oncology Inc.
  • Senior Management
  • Joshua H Bilenker, MD, Pres. & CEO
    Nisha Nanda, PhD, VP, Dev. Strategy
    Jennifer Burstein, VP, Fin.
    Jacob Van Naarden, CBO
  • Contact Info
  • Loxo Oncology Inc.
    Phone: (203) 653-3880
    281 Tresser Blvd.
    9th Floor
    Stamford, CT 06901
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register